Hedge fund mogul Bill Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan, his firm's big bet for 2014.» Read More
WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...
Some of Monday's midday movers:
NEW YORK, Nov 17- Hedge fund Omega Advisors expects to see the U.S. stock market's bull run continue into next year, fueled by steady economic growth and a corporate takeover boom. "My expectation is for the Standard& Poor's 500 to gain 7 percent to 9 percent in 2015," Steven Einhorn, Omega's vice chairman said on Monday. Omega, founded by Leon Cooperman two decades ago...
Actavis is buying Allergan for $66 billion. CNBC's Kate Kelly provides insight to speculation surrounding the benefit of the deal to Pershing Square's Bill Ackman.
*Baker Hughes rallies, Halliburton tumbles after deal. The M&A news partly offset the declines as Allergan agreed to be bought by Actavis while Halliburton said it would buy Baker Hughes. Allergan and Baker Hughes were the top point gainers on the S&P 500..
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
Allergan rose $15.20 or 7.7 percent, to $213.85. Baxter International Inc. fell$. 14 or. 2 percent, to $71.61. Boston Scientific Corp. fell$. 01 or. 1 percent, to $13.35.
*Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news offset the declines as Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis.
Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. The offer values Allergan at $219 per share and is $6 billion more than the price Valeant had last offered to pay. Allergan shares rose 6.6 percent to $211, earning Ackman a...
Nov 17- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc..
Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.
CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products. Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, both have grown rapidly in recent years through multibillion dollar acquisitions of other drugmakers.
CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.
NEW YORK— Pharmaceutical giant Actavis to buy Botox maker Allergan for $66 billion in cash-and-stock.
Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc. The offer values Allergan at $219 per share, compared with its Friday close of $198.65. Valeant's latest cash-and-stock offer is currently...
U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.
*Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout by Actavis.
Some of the names on the move ahead of the open.
*Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout deal by Actavis. *Baker Hughes rose 16.4 percent on news Halliburton would acquire it in a cash and stock transaction of about $34.6 billion. *Allergan added 4.5 percent as the Actavis buyout values the company as high as $65.5...